Abstract
The utilization of modern triiodinated radiocontrast agents for intravenous urography (IVU) is widely considered as a very safe procedure in patients free of currently well defined risk factors, amongst which the prominent ones are preexisting renal disease and diabetes mellitus complicated by deteriorated renal function (1,2,3). Whereas the incidence of nephrotoxicity accidents is extremely low in patients with no preexisting renal insufficiency, the risk of an acute, and sometimes definitive, deterioration of renal function following administration of radiocontrast agents has been evaluated as high as 90 % in insulin dependent diabetic patients with severe preexisting renal impairment (1).
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call